Logo image of CARA

CARA THERAPEUTICS INC (CARA) Stock Fundamental Analysis

NASDAQ:CARA - Nasdaq - US1407552082 - Common Stock - Currency: USD

5.32  -0.23 (-4.14%)

After market: 5.43 +0.11 (+2.07%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CARA. CARA was compared to 195 industry peers in the Pharmaceuticals industry. While CARA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CARA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CARA had negative earnings in the past year.
CARA had a negative operating cash flow in the past year.
CARA had negative earnings in 4 of the past 5 years.
CARA had a negative operating cash flow in each of the past 5 years.
CARA Yearly Net Income VS EBIT VS OCF VS FCFCARA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -161.70%, CARA is not doing good in the industry: 83.42% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -161.7%
ROE N/A
ROIC N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CARA Yearly ROA, ROE, ROICCARA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

With an excellent Gross Margin value of 91.31%, CARA belongs to the best of the industry, outperforming 93.47% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for CARA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CARA Yearly Profit, Operating, Gross MarginsCARA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

4

2. Health

2.1 Basic Checks

CARA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CARA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CARA has been reduced compared to 5 years ago.
CARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CARA Yearly Shares OutstandingCARA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CARA Yearly Total Debt VS Total AssetsCARA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

CARA has an Altman-Z score of -26.56. This is a bad value and indicates that CARA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -26.56, CARA is not doing good in the industry: 87.44% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.56
ROIC/WACCN/A
WACC9.58%
CARA Yearly LT Debt VS Equity VS FCFCARA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 11.03 indicates that CARA has no problem at all paying its short term obligations.
CARA has a Current ratio of 11.03. This is amongst the best in the industry. CARA outperforms 86.43% of its industry peers.
CARA has a Quick Ratio of 10.81. This indicates that CARA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.81, CARA belongs to the top of the industry, outperforming 85.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.03
Quick Ratio 10.81
CARA Yearly Current Assets VS Current LiabilitesCARA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CARA have decreased strongly by -612.03% in the last year.
The Revenue for CARA has decreased by -66.02% in the past year. This is quite bad
Measured over the past years, CARA shows a very negative growth in Revenue. The Revenue has been decreasing by -18.54% on average per year.
EPS 1Y (TTM)-612.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.05%
Revenue 1Y (TTM)-66.02%
Revenue growth 3Y-32.3%
Revenue growth 5Y-18.54%
Sales Q2Q%-51.56%

3.2 Future

The Earnings Per Share is expected to grow by 11.45% on average over the next years. This is quite good.
Based on estimates for the next years, CARA will show a very strong growth in Revenue. The Revenue will grow by 68.20% on average per year.
EPS Next Y40%
EPS Next 2Y22.74%
EPS Next 3Y13%
EPS Next 5Y11.45%
Revenue Next Year-25%
Revenue Next 2Y-44.1%
Revenue Next 3Y58.04%
Revenue Next 5Y68.2%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CARA Yearly Revenue VS EstimatesCARA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
CARA Yearly EPS VS EstimatesCARA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CARA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CARA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CARA Price Earnings VS Forward Price EarningsCARA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CARA Per share dataCARA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

CARA's earnings are expected to grow with 13.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.74%
EPS Next 3Y13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CARA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARA THERAPEUTICS INC

NASDAQ:CARA (4/15/2025, 8:00:02 PM)

After market: 5.43 +0.11 (+2.07%)

5.32

-0.23 (-4.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03 2025-03-03/amc
Earnings (Next)05-12 2025-05-12/amc
Inst OwnersN/A
Inst Owner Change-41.88%
Ins OwnersN/A
Ins Owner Change-0.04%
Market Cap24.31M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)22.19%
Min Revenue beat(2)-10.63%
Max Revenue beat(2)55%
Revenue beat(4)2
Avg Revenue beat(4)12.75%
Min Revenue beat(4)-17.21%
Max Revenue beat(4)55%
Revenue beat(8)4
Avg Revenue beat(8)-5.61%
Revenue beat(12)7
Avg Revenue beat(12)-4.97%
Revenue beat(16)8
Avg Revenue beat(16)-9.33%
PT rev (1m)0%
PT rev (3m)1100%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-15.55
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-13.56
FCFYN/A
OCF(TTM)-13.33
OCFYN/A
SpS1.56
BVpS-1.01
TBVpS-1.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -161.7%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.31%
FCFM N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 544.79%
Cap/Sales 14.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.03
Quick Ratio 10.81
Altman-Z -26.56
F-Score4
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)492.59%
Cap/Depr(5y)332.09%
Cap/Sales(3y)8.69%
Cap/Sales(5y)5.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-612.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.05%
EPS Next Y40%
EPS Next 2Y22.74%
EPS Next 3Y13%
EPS Next 5Y11.45%
Revenue 1Y (TTM)-66.02%
Revenue growth 3Y-32.3%
Revenue growth 5Y-18.54%
Sales Q2Q%-51.56%
Revenue Next Year-25%
Revenue Next 2Y-44.1%
Revenue Next 3Y58.04%
Revenue Next 5Y68.2%
EBIT growth 1Y56.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.9%
EBIT Next 3Y10.58%
EBIT Next 5Y5.61%
FCF growth 1Y34.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.84%
OCF growth 3YN/A
OCF growth 5YN/A